Dn B Asset Management As Moon Lake Immunotherapeutics Transaction History
Dn B Asset Management As
- $21.2 Billion
- Q1 2025
A detailed history of Dn B Asset Management As transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Dn B Asset Management As holds 10,311 shares of MLTX stock, worth $402,232. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,311
Previous 8,356
23.4%
Holding current value
$402,232
Previous $444,000
9.46%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding MLTX
# of Institutions
161Shares Held
55.3MCall Options Held
481KPut Options Held
229K-
Bvf Inc San Francisco, CA19.8MShares$770 Million33.91% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$331 Million35.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.97MShares$116 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$108 Million1.75% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.48MShares$57.7 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.44B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...